financetom
Business
financetom
/
Business
/
Interactive Brokers Second-Quarter Earnings Top Views as Trading Volume Buoys Revenue
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Interactive Brokers Second-Quarter Earnings Top Views as Trading Volume Buoys Revenue
Jul 16, 2024 2:13 PM

04:46 PM EDT, 07/16/2024 (MT Newswires) -- Interactive Brokers ( IBKR ) late Tuesday reported second-quarter earnings that exceeded analysts' estimates as the brokerage's revenue rose year over year on the back of increased customer trading volume.

Adjusted per-share earnings rose to $1.76 during the three months ended June 30 from $1.32 a year earlier, topping the $1.74 consensus on Capital IQ. Net revenue increased to $1.23 billion from $1 billion. Five analysts polled by Capital IQ expected $1.27 billion.

Commission revenue gained 26% to $406 million, led by double-digit volume gains in options, stocks, and futures. The number of customer accounts increased 28% year over year to 2.92 million, Interactive Brokers ( IBKR ) said.

Net interest income advanced 14% to $792 million amid higher interest rates and customer credit balances.

As previously reported, the brokerage recognized a $48 million loss in the second quarter on positions taken over as customer accommodation following a technical glitch at the New York Stock Exchange on June 3. The temporary issue caused Berkshire Hathaway's (BRK.A) class A shares to appear to be down nearly 100% before the NYSE halted trading in the shares. The issue was resolved the same day.

Price: 125.00, Change: +1.34, Percent Change: +1.08

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Another Boeing Whistleblower Dies, This Time Due To Sudden Infection
Another Boeing Whistleblower Dies, This Time Due To Sudden Infection
May 2, 2024
Boeing Co ( BA ) shares are trading higher on Thursday, inline with a broader market upswing in response to a Wednesday decision by the Fed to keep interest rates steady for the upcoming period. The company appeared unaffected by the latest chapter in its saga of bad publicity: the sudden death of yet another whistleblower, who had sounded the...
Burlington Stores' Earnings, Sales Growth Prospects Have Likely Improved, UBS Says in Upgrade
Burlington Stores' Earnings, Sales Growth Prospects Have Likely Improved, UBS Says in Upgrade
May 2, 2024
03:42 PM EDT, 05/02/2024 (MT Newswires) -- Burlington Stores ( BURL ) is likely to generate better sales growth than previously expected while its earnings growth outlook has improved amid increased conviction that the off-price retailer and its peers will continue to gain market share from department stores, UBS Securities said Thursday. The brokerage upgraded its rating on the Burlington...
Update: Market Chatter: Nomura, Mizuho Face Over $100 Million in Losses on All Blue Fund's Failed Trades
Update: Market Chatter: Nomura, Mizuho Face Over $100 Million in Losses on All Blue Fund's Failed Trades
May 2, 2024
03:39 PM EDT, 05/02/2024 (MT Newswires) -- (Updates with further details, companies declining or not responding to request for comment in second to fourth paragraphs) Nomura Holdings ( NMR ) and Mizuho Financial Group ( MFG ) are facing over $100 million in potential losses tied to several failed stock trades by investment fund All Blue Capital, Bloomberg reported, citing...
Sarepta Therapeutics to Benefit as Regulatory Review on DMD Therapy Picks Up, Morgan Stanley Says
Sarepta Therapeutics to Benefit as Regulatory Review on DMD Therapy Picks Up, Morgan Stanley Says
May 2, 2024
03:42 PM EDT, 05/02/2024 (MT Newswires) -- Sarepta Therapeutics' ( SRPT ) regulatory review of its Elevidys therapy for Duchenne muscular dystrophy is advancing faster than anticipated, Morgan Stanley said in a report emailed Thursday. Overall, we view acceleration of the [US Food and Drug Administration] review process into labeling discussions ahead of schedule as a positive, Morgan Stanley said....
Copyright 2023-2026 - www.financetom.com All Rights Reserved